IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study
Zou, YC; Hu, DY; Yang, XC; Xu, ZM; Cui, LA; Liu, XH; Wei, Y; Gao, MM
关键词Simvastatin Acute Coronary Artery Syndromes Safty
刊名CHINESE MEDICAL JOURNAL
2003-06-01
116期:6页:853-856
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]HEART-DISEASE ; MYOCARDIAL-INFARCTION ; CHOLESTEROL LEVELS ; CLINICAL EVENTS ; PRAVASTATIN ; REDUCTION ; HYPERCHOLESTEROLEMIA ; ATHEROSCLEROSIS ; PREVENTION ; THERAPY
英文摘要

Objective To investigate whether patients, who are at risk of major acute coronary events, are safe to undergo and benefit from early intervention after using simvastatin.

Methods The study, was a randomized, open, two-dosage-control led trial to evaluate the safety and benefits of simvastatin administered to 197 patients (10 mg group, n = 98 and 20 mg group, n = 99), within 48 hours of hospitalization for a diagnosis of unstable angina or acute myocardial infarction (MI), with total cholesterol (TC) greater than or equal to180 mg/dL or low-density lipoprotein cholesterol (LDL-C) greater than or equal to100 mg/dL. Lipid levels were measured immediately, followed by the 3rd, 6th and 12th month after admission and all adverse events were recorded during follow-up.

Results TC levels fell by 10.15% and 14.52% in the 10 mg and 20 mg groups ( P < 0.05), and LDL-C levels fell 13.87% and 19.38% in the 10 mg and 20 mg groups, respectively ( P < 0.01), 12 months after using simvastatin. The rates of achieving target TC reached 26.3% and 36.5% in the 10 mg and 20 mg groups (P < 0.01), and that of LDL-C reached 28.2% and 40.3% in the 10 mg and 20 mg groups, respectively ( P < 0.01). There were higher rates of MI and re-hospitalization resulting from angina pectoris and revascularization in the 10 mg group compared with the 20 mg group.

Conclusions The results suggest that early intervention with the HMG-CoA reductase inhibitor, simvastatin, in acute coronary syndromes is possible and safe. It also indicates that the clinical dosage of simvastatin are relatively smaller than that for satisfactory lipid control in patients with acute coronary syndromes.

语种英语
WOS记录号WOS:000184024900013
Citation statistics
Cited Times:3[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53859
Collection北京大学第二临床医学院_心血管内科
作者单位1.Capital Univ Med Sci, Chaoyang Hosp, Ctr Heart, Beijing 100020, Peoples R China
2.Peking Univ, Renmin Hosp, Dept Cardiol, Beijing 100044, Peoples R China
Recommended Citation
GB/T 7714
Zou, YC,Hu, DY,Yang, XC,et al. Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study[J]. CHINESE MEDICAL JOURNAL,2003,116(6):853-856.
APA Zou, YC.,Hu, DY.,Yang, XC.,Xu, ZM.,Cui, LA.,...&Gao, MM.(2003).Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.CHINESE MEDICAL JOURNAL,116(6),853-856.
MLA Zou, YC,et al."Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study".CHINESE MEDICAL JOURNAL 116.6(2003):853-856.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Zou, YC]'s Articles
[Hu, DY]'s Articles
[Yang, XC]'s Articles
百度学术
百度学术Similar articles in
[Zou, YC]'s Articles
[Hu, DY]'s Articles
[Yang, XC]'s Articles
必应学术
必应学术Similar articles in
[Zou, YC]'s Articles
[Hu, DY]'s Articles
[Yang, XC]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.